Biosimilars in immune-mediated inflammatory diseases: Initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody

Journal of Internal Medicine

Volumn 279, Issue 1, 2016, Pages 41-59

  Isaacs, J D ^a   Cutolo, M ^b   Keystone, E C ^c   Park, W ^d   Braun, J ^e  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF TORONTO   (Canada)

^d Inha University Hospital   (South Korea)

^e RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Biosimilars; Crohn's disease; CT P13; Infliximab; Rheumatoid arthritis; Ulcerative colitis

Indexed keywords

INFLIXIMAB; BIOSIMILAR AGENT; CT-P13; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; INFLAMMATION;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84949626656     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12432     Document Type: Review

References (77)

1. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007; 83: 251-60.
2. Nast A, Mrowietz U, Kragballe K et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis: a multinational cross-sectional study. Arch Dermatol Res 2013; 305: 899-907.
3. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206.
4. World Health Organization. Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed 1 October 2014).
5. Abraham J. Developing oncology biosimilars: an essential approach for the future. Semin Oncol 2013; 40(Suppl. 1): S5-24.
6. Lorenz HM, Braun J, Kruger K, Schneider M. Implementation and use of biosimilars in the therapy of inflammatory rheumatic diseases: statement of the German Society of Rheumatology. Z Rheumatol 2014; 73: 784-6.
7. Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013; 38: 914-24.
8. Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol 2014; 10: 981-3.
9. Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol 2011; 5: 741-54.
10. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014; 8: 431-5.
11. Feagan BG, Choquette D, Ghosh S et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177-83.
12. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16: 22-6.
13. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-6.
14. Tothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014; 15(Suppl. 1): S5-11.
15. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 2013; 5: 561-74.
16. Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30: 1186-90.
17. Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf 2009; 32: 811-7.
18. Zuniga L, Calvo B. Biosimilars: pharmacovigilance and risk management. Pharmacoepidemiol Drug Saf 2010; 19: 661-9.
19. European Medicines Agency. Guideline on Similar Biological Medicine Products. Draft. 22 May 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf (accessed 20 October 2014).
20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab). 27 June 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf (accessed 2 October 2014).
21. European Medicines Agency. Remsima (infliximab). Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf (accessed 22 October 2014).
22. European Medicines Agency. Remicade (infliximab). Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf (accessed 22 October 2014).
23. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20.
24. Jung SK, Lee KH, Jeon JW et al. Physicochemical characterization of Remsima®. MAbs 2014; 6: 1163-77.
25. Kurki P, Bielsky MC, Working Party on Similar Biological Medicinal Products of Committee for Medicinal Products for Human Use (CHMP). ECCO position challenged by European drug regulators. J Crohns Colitis 2014; 8: 258.
26. Shealy DJ, Cai A, Staquet K et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010; 2: 428-39.
27. Yoo D-H, Park W, Shim S-C, Suh C-H, Yun J, Pyo T. A randomized, double-blind, three-arm, parallel group, single-dose study to compare the pharmacokinetics, safety, and tolerability of three formulations of infliximab (CT-P13, EU-sourced infliximab and US-sourced infliximab) in healthy volunteers. Arthritis Rheumatol 2014; 11(Suppl.): S664. (1509).
28. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12.
29. Park W, Jaworski J, Brzezicki J et al. A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study. Ann Rheum Dis 2013; 72(Suppl. 3): 516. [FRI0421].
30. Yoo DH, Racewicz A, Brzezicki J et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis 2013; 72(Suppl. 3): 73. [OP0068].
31. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
32. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
33. Westhovens R, Yocum D, Han J et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075-86.
34. Yoo D, Park W, Miranda P et al. Inhibition of radiographic progression and its Bath AS Disease Activity Index association with clinical parameters in RA patients treated with CT-P13 and innovator infliximab in PLANETRA study. Ann Rheum Dis 2014; 73(Suppl. 2): 234-5. THU0158.
35. Yoo DH, Prodanovic N, Jaworski J et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013; 65: 3319. (L1).
36. Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Ohtsubo H, Nambu Y. Investigation of the pharmacokinetic equivalence, efficacy and safety of the biosimilar product, CT-P13, with its original drug, infliximab. Mod Rheumatol 2014; 24: S60. (W14-4).
37. Park W, Miranda P, Brzosko M et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013; 65: 3326. (L15).
38. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2014; 60: 951-6.
39. British Thoracic Society Standards of Care. C. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5.
40. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72.
41. Yoo DH, Park W, Brzosko M et al. Disease activity assessment using the DAS28, CDAI and SDAI and effect of anti-drug antibody on clinical response in a randomized, double-blind, comparative trial of CT-P13 and innovator infliximab: PLANETRA study. Ann Rheum Dis 2014; 73(Suppl. 2): 235. [THU0159].
42. Park W, Woo DH, Szanto S et al. Clinical response of disease activity, disability and mobility indices in relation to anti-drug antibody in the PLANETAS study. Ann Rheum Dis 2014; 73(Suppl. 2): 121. [OP0157].
43. European Medicines Agency. Guideline on Similar Biological Medicine Products Containing Monoclonal Antibodies - Non-clinical and Clinical Issues. Draft. 30 May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf (accessed 13 April 2015).
44. Blandizzi C, Gionchetti P, Armuzzi A et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014; 27: 1-10.
45. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
46. Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res 2014; 163: 533-56.
47. Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA. Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 2014; 32: 415-23.
48. Ueda N, Tsukamoto H, Mitoma H et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis 2013; 19: 1224-31.
49. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-32.
50. Dorner T, Strand V, Castaneda-Hernandez G et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-8.
51. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013; 72: 1589-93.
52. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72: 315-8.
53. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-2.
54. Gecse KB, Khanna R, van den Brink GR et al. Biosimilars in IBD: hope or expectation? Gut 2013; 62: 803-7.
55. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014; 28: 465-71.
56. European Commission. Consensus Information Paper 2013. What you need to know about biosimilar medicinal products. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf (accessed 5 October 2014).
57. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 2012; 30: S102-6.
58. Haustein R, de Millas C, Hoer A, Haussler B. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J 2012; 1: 120-6.
59. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15(Suppl. 1): S65-71.
60. Kim J, Hong J, Kudrin A. 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheumatol 2014; 11(Suppl.): S512. (abstract 1166).
61. McCarthy G, Ebel BC, Guy H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health 2013; 16: A558. (PMS22).
62. Gascon P, Tesch H, Verpoort K et al. Clinical experience with Zarzio(R) in Europe: what have we learned? Support Care Cancer 2013; 21: 2925-32.
63. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol 2014; 41(Suppl. 3): S13-20.
64. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
65. World Health Organization. Biological Qualifier. An INN Proposal. Programme on International Nonproprietary Names (INN). INN Working Doc. 14.342. Revised draft July 2014. Available at: http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf?ua=1 (accessed 18 November 2014).
66. European Medicines Agency. Report on organisational mattters; Committee for Medicinal Products for Human Use (CHMP) meeting, 22-25 September 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Annex_to_CHMP_highlights/2014/10/WC500175252.pdf (accessed 18 November 2014).
67. Sekhon S, Rai R, McClory D et al. Patient perspectives on the introduction of subsequent entry biologics in Canada. Arthritis Rheumatol 2014; 11(Suppl.): S663 (abstract 1507).
68. Wilkins AR, Venkat MV, Brown AS et al. Patient perspectives on biosimilar insulin. J Diabetes Sci Technol 2014; 8: 23-5.
69. National Rheumatoid Arthritis Society. NRAS position paper on biosimilar medicines. 14 August 2014. Available at: http://www.nras.org.uk/data/files/About%20RA/How%20is%20RA%20managed/NRAS%20Biosimilars%20Position%20Paper%20Final.pdf (accessed 23 October 2014).
70. Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum 2014; 43: 479-88.
71. Australian Government. Department of Health. Therapeutic Goods Administration. Evaluation of biosimilars. Version 1.0. Available at: https://www.tga.gov.au/evaluation-biosimilars (accessed 10 August 2015).
72. Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs), 2010. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf (accessed 20 October 2014).
73. Government of India, Department of Biotechnology, Ministry of Science & Technology, Central Drugs Standard Control Organization, Ministry of Health & Family Welfare. Guidelines on Similar Biologics. Regulatory Requirements for Marketing Authorization in India. 2012. Available at: http://dbtbiosafety.nic.in/Files/CDSCO-DBTSimilarBiologicsfinal.pdf (accessed 20 October 2014).
74. GaBI Journal Editor. Biosimilar development and regulation in Japan. Generics Biosimilars Initiat J 2013; 2: 207-8.
75. South Korean guidelines for biosimilars. 2012. GaBI online. Available at: http://www.gabionline.net/Guidelines/South-Korean-guidelines-for-biosimilars (accessed 20 October 2014).
76. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. Guidance for Industry. 2015. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf (accessed 22 May 2015).
77. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.